CTOs on the Move

JenaValve

www.jenavalve.com

 
JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.
  • Number of Employees: 100-250
  • Annual Revenue: $250-500 Million
  • www.jenavalve.com
  • 1000 N. West Street Suite 1200
    Wilmington, DE USA 19801
  • Phone: 302.295.4897

Executives

Name Title Contact Details

Similar Companies

Inspiris

Inspiris is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Code Blue

For more than 25 years, Code Blue Corporation has been the industry leading manufacturer of durable emergency communication solutions. The pioneer in developing and producing vandal-resistant Blue Light Emergency Phones at thousands of education, corporate, hospital, airport and municipal locations around the world, Code Blue’s expansion includes the innovation of advanced public address and mass notification systems to provide a complete end-to-end solution. Founded to address the growing need for sophisticated audio security solutions, Code Blue offers American-made Help Point®, Emergency Signaling, Incident Response and Systems Management products that are innovative, rugged, powerful and easily integrated. Code Blue’s evolution continues with the engineering of new software and hardware designed to meet the ever-changing needs of customers who require an advanced level of incident deterrence that establishes a safe environment. No matter where you go, you can feel safe knowing that there is help at the touch of a button.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.

Gereonics

Gereonics is a Solana Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glaukos

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world`s leading causes of blindness. Glaukos has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. The company launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device, in the United States in 2012. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. Glaukos believes the iStent is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, the company completed an initial public offering and its shares are now traded on the New York Stock Exchange under the ticker symbol "GKOS". Founded in 1998, Glaukos is based in San Clemente, California.